background
hospitalacquir
pneumonia
hap
defin
radiolog
confirm
pneumonia
occur
h
hospit
nonintub
patient
empir
treatment
regimen
use
broadspectrum
antimicrobi
aim
evalu
accuraci
diagnosi
hap
describ
demograph
microbiolog
featur
patient
hap
method
medic
surgic
inpati
receiv
intraven
antimicrobi
clinic
diagnosi
hap
uk
tertiari
care
hospit
april
identifi
demograph
clinic
detail
record
find
total
adult
patient
clinic
diagnosi
hap
identifi
broadspectrum
antimicrobi
prescrib
primarili
piperacillinetazobactam
coamoxiclav
sputum
patient
obtain
cultur
sixtyf
percent
patient
radiolog
evid
newprogress
infiltr
time
hap
treatment
therefor
meet
hap
diagnost
criteria
american
thorac
societi
infecti
diseas
societi
america
guidelin
radiolog
confirm
hap
associ
higher
level
inflammatori
marker
sputum
cultur
posit
previou
surgeri
andor
endotrach
intub
associ
radiolog
confirm
hap
bacteri
pathogen
identifi
sputum
sampl
radiolog
confirm
hap
patient
gramneg
bacilli
n
staphylococcu
aureu
n
gramneg
bacteria
tend
resist
coamoxiclav
suscept
ciprofloxacin
piperacillinetazobactam
meropenem
five
six
aureu
isol
meticillin
suscept
suscept
doxycyclin
conclus
wardlevel
hospit
practic
hap
overus
diagnosi
may
inaccur
case
object
radiolog
criteria
appli
radiolog
confirm
hap
repres
distinct
clinic
microbiolog
phenotyp
potenti
risk
factor
identifi
could
repres
target
prevent
intervent
syndrom
hospitalacquir
pneumonia
hap
defin
pneumonia
occur
nonintub
patient
h
hospit
therefor
incub
time
admiss
distinct
ventilatorassoci
pneumonia
vap
defin
pneumonia
occur
h
mechan
ventil
intub
patient
hap
may
suspect
patient
develop
new
symptom
sign
consist
respiratori
tract
infect
fever
abnorm
chest
examin
purul
sputum
tachypnoea
impair
oxygen
laboratori
result
consist
inflamm
rais
white
cell
count
creactiv
protein
howev
diagnosi
hap
also
requir
radiolog
demonstr
new
progress
lung
infiltr
american
thorac
societyinfecti
diseas
societi
america
atsidsa
guidelin
manag
hap
highlight
gramneg
bacilli
frequent
occur
pathogen
hap
staphylococcu
aureu
emerg
caus
much
literatur
use
describ
aetiolog
hap
relat
vap
nosocomi
pneumonia
occur
specif
intens
care
unit
icu
nursinghomeacquir
pneumonia
overal
known
pathogenesi
microbiolog
vap
facilit
eas
obtain
deep
respiratori
sampl
bronchoalveolar
lavag
intub
patient
importantli
evidencebas
care
bundl
prevent
vap
hap
empir
treatment
hap
aim
includ
cover
nosocomi
pathogen
especi
gram
neg
bacteria
therefor
necessit
use
broadspectrum
agent
coamoxiclav
piperacillinetazobactam
attend
risk
antibioticassoci
diarrhoea
c
difficil
infect
select
antimicrobi
resist
patient
environment
flora
also
high
cost
accur
diagnosi
hap
therefor
essenti
ensur
appropri
use
antimicrobi
aim
studi
retrospect
evalu
accuraci
diagnosi
hap
inpati
acut
intern
medicin
gener
surgic
ward
receiv
intraven
antimicrobi
clinic
diagnosi
hap
made
patient
team
demograph
microbiolog
featur
patient
radiolog
confirm
hap
describ
retrospect
observ
cohort
studi
medic
surgic
inpati
receiv
intraven
antimicrobi
clinic
diagnosi
hap
tertiari
care
hospit
edinburgh
uk
data
collect
part
larg
prospect
audit
antimicrobi
prescrib
inpati
within
acut
intern
medicin
gener
surgeri
ward
royal
infirmari
edinburgh
rie
month
april
april
patient
treat
intraven
antimicrobi
h
indic
identifi
review
consult
infecti
diseas
physician
antimicrobi
pharmacist
includ
current
studi
patient
cohort
receiv
intraven
antimicrobi
document
clinic
diagnosi
hap
exclud
vap
cap
demograph
data
medic
histori
admiss
detail
includ
death
admiss
clinic
diagnosi
deduc
primari
clinic
team
microbiolog
sampl
radiolog
investig
collect
antimicrobi
suscept
test
carri
use
european
committe
antimicrobi
suscept
test
eucast
methodolog
presenc
sign
andor
symptom
consist
respiratori
tract
infect
assum
base
clinic
diagnosi
hap
made
patient
clinician
h
admiss
hospit
classifi
radiolog
confirm
hap
studi
chest
xray
evid
new
progress
lung
infiltr
requir
report
radiologist
consist
atsidsa
guidelin
fisher
exact
test
use
compar
categor
variabl
one
cell
contain
five
fewer
subject
chisquar
test
use
cell
contain
five
subject
shapiroewilk
wtest
nonnorm
use
assess
distribut
continu
data
mannewhitney
utest
use
data
normal
distribut
data
analys
use
statsdirect
softwar
version
statsdirect
altrincham
uk
p
consid
statist
signific
outcom
icu
admiss
intub
ventil
timeperiod
total
admiss
eight
ward
rie
review
overal
adult
inpati
receiv
h
intraven
antimicrobi
treat
clinic
diagnosi
hap
patient
intraven
antimicrobi
tabl
cohort
patient
elderli
median
age
year
major
patient
age
year
male
patient
admit
medic
ward
surgic
ward
comorbid
exampl
chronic
obstruct
pulmonari
diseas
heart
failur
cardiocerebrovascular
diseas
widespread
cohort
reflect
inpati
mortal
tabl
ii
median
number
comorbid
patient
patient
treat
hap
underw
surgic
procedur
gener
anaesthet
prior
diagnosi
treatment
tabl
ii
slightli
higher
percentag
previous
undergon
endotrach
intub
admiss
reflect
patient
requir
intub
airway
manag
mechan
ventil
icu
intub
gener
anaesthesia
six
patient
treat
clinic
diagnosi
hap
requir
icu
admiss
mechan
ventil
follow
clinic
diagnosi
hap
major
patient
clear
lung
field
report
radiologist
admiss
chest
xray
nine
percent
patient
consolid
report
admiss
repres
initi
present
communityacquir
pneumonia
aspir
pneumonia
suspicion
treatment
hap
aris
h
admiss
accord
local
guidelin
treatment
hap
piperacillinetazobactam
frequent
use
antimicrobi
prescrib
includ
patient
tabl
ii
coamoxiclav
second
wide
prescrib
antimicrobi
use
case
chest
imag
found
evid
new
progress
infiltr
chest
imag
perform
four
patient
patient
exclud
follow
analys
radiolog
confirm
hap
appear
repres
distinct
clinic
phenotyp
significantli
higher
level
inflammatori
marker
white
cell
count
neutrophil
creactiv
protein
p
patient
tabl
iii
patient
radiolog
confirm
hap
like
white
cell
count
greater
upper
limit
local
refer
rang
odd
ratio
confid
interv
ci
p
leucopenia
observ
one
patient
group
total
durat
intraven
antimicrobi
therapi
consid
patient
radiolog
confirm
hap
longer
median
minimum
durat
treatment
day
vs
day
p
tabl
ii
suggest
two
group
clinic
differ
signific
differ
use
piperacillinetazobactam
coamoxiclav
vancomycin
ciprofloxacin
meropenem
patient
without
radiolog
confirm
hap
mortal
rate
admiss
patient
radiolog
confirm
hap
patient
requir
admiss
icu
mechan
ventil
follow
hap
diagnosi
group
without
radiolog
confirm
patient
went
requir
icu
admiss
mortal
rate
admiss
p
demograph
associ
radiolog
confirm
hap
patient
characterist
admiss
detail
compar
patient
treat
hap
without
radiolog
confirm
newprogress
infiltr
tabl
ii
admit
surgic
ward
ci
p
undergo
surgeri
requir
gener
anaesthesia
intub
p
endotrach
intub
indic
p
associ
radiolog
confirm
hap
surgic
patient
differ
emergencyelect
admiss
patient
group
median
two
medic
comorbid
asid
ckd
comorbid
associ
radiolog
confirm
hap
rate
microbiolog
sampl
patient
radiolog
confirm
hap
similar
overal
popul
patient
treat
clinic
suspicion
hap
bacteri
pathogen
identifi
sputum
sampl
patient
radiolog
confirm
hap
tabl
iv
major
bacteri
speci
identifi
sputum
sampl
gramneg
bacilli
n
aureu
n
sputum
sampl
obtain
six
patient
without
radiolog
confirm
hap
none
yield
growth
bacteri
pathogen
blood
cultur
drawn
patient
radiolog
confirm
hap
bacteraemia
infrequ
occur
four
patient
sputum
cultur
obtain
patient
bacteraemia
gramneg
bacteria
respons
two
bloodstream
infect
mrsa
pneumonia
account
one
patient
pneumonia
bacteraemia
associ
hap
clear
lung
field
admiss
chest
xray
throat
swab
qpcr
test
respiratori
pathogen
obtain
patient
neg
case
mrsa
found
five
mrsa
screen
taken
time
admiss
identifi
one
sputum
sampl
one
blood
cultur
differ
patient
patient
posit
mrsa
screen
antibiogram
antimicrobi
suscept
bacteria
isol
sputum
sampl
shown
supplementari
tabl
overal
gramneg
bacteria
tend
resist
amoxicillin
coamoxiclav
suscept
ciprofloxacin
gentamicin
piperacillinetazobactam
meropenem
five
six
aureu
isol
suscept
flucloxacillin
six
suscept
doxycyclin
includ
one
mrsa
isol
mrsa
sputum
isol
suscept
vancomycin
retrospect
evalu
cohort
medic
surgic
inpati
treat
clinic
diagnosi
hap
appli
atsidsa
hap
guidelin
patient
identifi
patient
radiolog
confirm
hap
therefor
appear
wardlevel
hospit
practic
institut
hap
overus
diagnosi
may
inaccur
onethird
case
surgic
ward
admiss
undergo
surgeri
gener
anaesthesia
endotrach
intub
indic
associ
radiolog
confirm
hap
atsidsa
guidelin
describ
intub
mechan
ventil
risk
factor
develop
nosocomi
pneumonia
literatur
cite
support
statement
describ
vap
ie
develop
pneumonia
patient
mechan
ventil
hypothesisgener
univari
analysi
data
suggest
intub
ventil
especi
associ
surgeri
may
continu
risk
factor
pneumonia
even
follow
extub
therefor
relev
factor
assess
nonintub
patient
new
respiratori
sign
symptom
hospit
pathogenesi
hap
may
therefor
often
relat
microaspir
oropharyng
content
around
cuff
endotrach
et
tube
paralys
intub
patient
surgeri
without
necessarili
prolong
period
mechan
ventil
critic
ill
ie
vap
systemat
literatur
review
airway
manag
strategi
reduc
incid
vap
critic
ill
ventil
patient
icu
intervent
includ
continu
aspir
subglott
secret
use
special
et
tube
vs
standard
et
tube
use
heat
moistur
exchang
shown
lower
vap
rate
separ
studi
persist
et
tube
cuff
pressur
cmh
also
associ
risk
vap
intervent
could
also
evalu
intub
patient
undergo
surgeri
similarli
critic
ill
ventil
patient
oral
hygien
chlorhexidin
mouthwash
shown
reduc
rate
vap
includ
compon
success
evalu
vap
care
bundl
chlorhexidin
mouthwash
would
inexpens
measur
use
immedi
preand
postop
period
surgic
patient
oral
care
chlorhexidin
mouthwash
mechan
clean
shown
associ
reduc
rel
risk
pneumonia
metaanalysi
incorpor
nonventil
hospit
inpati
nurs
home
resid
though
high
risk
bia
includ
studi
postop
factor
like
import
develop
hap
includ
bedbound
reduc
chest
wall
movement
therefor
reduc
clearanc
secret
due
pain
drowsi
secondari
opiat
analges
approxim
onethird
patient
treat
suspect
hap
studi
chest
xray
comput
tomographi
ct
exclud
pneumon
infiltr
therefor
altern
diagnosi
may
miss
phenotyp
describ
ventil
icu
patient
respiratori
sign
infiltr
chest
imag
label
nosocomi
tracheobronch
associ
longer
icu
admiss
ventil
time
prospect
data
describ
necess
antimicrobi
lack
studi
phenotyp
nonintub
patient
may
valuabl
may
account
case
studi
without
radiolog
chang
consist
hap
noninfect
altern
includ
atelectasi
pulmonari
embol
underli
lung
diseas
chronic
obstruct
pulmonari
diseas
present
patient
treat
hap
studi
asthma
unwel
patient
label
hap
may
subdiaphragmat
caus
sepsi
result
clinic
find
given
demonstr
difficulti
reach
reliabl
clinic
diagnosi
hap
microbiolog
test
confirm
infect
aetiolog
becom
even
import
sputum
sampl
obtain
patient
treat
hap
low
rate
may
reflect
difficulti
obtain
suitabl
deep
specimen
nonintub
patient
degre
respiratori
distress
weak
patient
biomark
pulmonari
infect
would
help
establish
likelihood
infect
aetiolog
justifi
use
empir
antimicrobi
prior
cultur
result
comparison
communityacquir
pneumonia
cultureposit
rate
sputum
sampl
institut
report
bacteri
pathogen
identifi
sampl
patient
radiolog
confirm
hap
therefor
greater
potenti
influenc
manag
studi
gramneg
bacilli
aureu
identifi
pathogen
frequent
occur
cap
pathogen
isol
remaind
case
sputum
sampl
obtain
result
growth
respiratori
commens
yeast
antimicrobi
resist
signific
gramneg
isol
display
resist
amoxicillin
coamoxiclav
suscept
piperacillinetazobactam
howev
overal
number
sputum
cultur
obtain
patient
low
reduc
util
data
describ
microbiolog
hap
addit
recogn
potenti
contamin
sputum
sampl
oropharyng
colon
import
issu
especi
consid
prescript
broadspectrum
antimicrobi
cover
suscept
pattern
pathogen
pragmat
one
would
aim
cover
speci
identifi
sputum
sampl
patient
hap
discuss
inabl
routin
obtain
deep
respiratori
tract
specimen
eg
bal
nonintub
patient
hinder
microbiolog
diagnosi
hap
largest
report
microbiolog
hap
come
retrospect
cohort
studi
us
inpati
databas
patient
cultureposit
pneumonia
includ
patient
hap
aureu
account
case
pseudomona
spp
klebsiella
spp
haemophilu
spp
e
coli
enterobact
spp
acinetobact
spp
overal
gramneg
pathogen
isol
hap
case
complic
factor
convent
culturebas
test
sampl
patient
suspect
hap
fact
like
alreadi
receiv
antimicrobi
prior
sampl
impair
sensit
pathogen
detect
use
culturebas
techniqu
qpcr
test
detect
quantif
eight
key
bacteri
caus
pneumonia
includ
aureu
e
coli
p
aeruginosa
sputum
sampl
recent
describ
could
repres
use
tool
investig
suspect
hap
six
patient
hap
throat
swab
obtain
qpcr
respiratori
viru
pneumonia
test
case
neg
nosocomi
influenza
account
signific
proport
influenza
case
canadian
surveil
programm
use
admiss
critic
care
ward
marker
influenza
season
scotland
similar
preced
year
signific
increas
case
howev
lack
consist
test
influenza
viru
patient
hap
preclud
conclus
incid
nosocomi
influenza
caus
hap
studi
period
util
respiratori
virusmycoplasma
test
workup
suspect
hap
limit
studi
radiolog
confirm
hap
primarili
deriv
result
chest
xray
patient
underw
ct
may
lead
underdetect
pulmonari
infiltr
compar
ct
studi
patient
present
emerg
depart
respiratori
symptom
underw
chest
xray
ct
demonstr
xray
poor
sensit
detect
pulmonari
infiltr
comparison
ct
sensit
time
ct
scan
specifi
studi
therefor
confound
factor
may
possibl
delay
xray
ct
allow
develop
detect
infiltr
case
hap
suspect
clinic
chest
xray
show
newprogress
lung
infiltr
may
role
ct
scan
addit
emerg
evid
role
lung
ultrasound
detect
pulmonari
infiltr
cap
data
suggest
superior
chest
xray
compar
ct
gold
standard
limit
lie
case
control
analysi
perform
repeat
futur
control
cohort
hospit
inpati
clinic
suspicion
hap
furthermor
studi
identifi
patient
receiv
intraven
antimicrobi
therebi
select
patient
perceiv
sever
ill
case
identifi
antimicrobi
prescrib
audit
recommend
made
parent
team
regard
antimicrobi
manag
wherea
occur
clinic
diagnosi
hap
made
patient
team
would
influenc
may
alter
subsequ
manag
could
therefor
confound
mortal
data
present
although
signific
differ
observ
patient
without
radiolog
confirm
hap
studi
describ
featur
radiolog
confirm
hap
cohort
uk
inpati
potenti
risk
factor
identifi
hypothesisgener
caseecontrol
analysi
use
patient
treat
suspicion
hap
without
consist
radiolog
previou
surgeri
andor
endotrach
intub
found
associ
radiolog
confirm
hap
significantli
clinic
diagnosi
hap
may
inaccur
onethird
case
consist
chang
chest
imag
also
highlight
lack
microbiolog
sampl
patient
receiv
broadspectrum
antimicrobi
clinic
diagnosi
hap
direct
work
hap
highlight
supplementari
tabl
ii
improv
accuraci
hap
diagnosi
essenti
sinc
around
onethird
patient
cohort
expos
broadspectrum
antimicrobi
potenti
unnecessarili
may
altern
diagnosi
requir
differ
investig
manag
